Table 1.
Changes in gastrointestinal symptom scores in both groups between the screening week and end of treatment
| Groups | Screening week, mean±SD | End of treatment (week 3), mean±SD | P-value | |
|---|---|---|---|---|
| Number of stools per week | Placebo | 19.7±8.3 | 15.5±13.6 | 0.12 |
| SBI | 18±5.3 | 13.6±5.4 | 0.07 | |
| Abdominal pain (Likert scale: 0 no pain; 4, severe pain) | Placebo | 2.1±0.7 | 1.6±0.7 | 0.08 |
| SBI | 2.4±0.6 | 1.7±0.9 | 0.02 | |
| Stool form (Bristol stool scale: 1–7) | Placebo | 5.1±0.6 | 4.2±2 | 0.28 |
| SBI | 5.3±0.8 | 4.2±1.2 | 0.05 |
Abbreviation: SBI: serum-derived bovine immunoglobulin.